Table 2 B characteristics of patients included in the analysis 12 months after initiation of nintedanib treatment in study 2

Age, years

74.0 (70-79)

71 (62-76)

n.s

Gender, Male/Female

11/4

3/2

n.s

BMI

23.3 (20.0-25.4)

23.4 (18.5-31.2)

n.s

BSA (m2)

1.62 (1.57-1.68)

1.81 (1.44-1.93)

n.s

FEV1/FVC (G)(%)

86.9 (83.8-93.8)

89.0 (83.0-90.5)

n.s

FVC (ml)

2180 1890-2600)

2190 (980-2210)

n.s

%FVC (%)

71.1 (56.7-76.4)

54.2 (34.2-75.2)

n.s

KL-6 (U/mL)

1136 (499-1620)

1020 649-1580)

n.s